secwatch.observer — SEC 8-K summary
======================================

Issuer:     Niagen Bioscience, Inc. (NAGE)
CIK:        0001386570
Form:       8-K
Filed at:   2025-11-04T23:59:59+00:00
Accession:  0001386570-25-000021
Event type: earnings
Sentiment:  positive
Materiality: 0.80
Item codes: 2.02, 7.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Niagen Bioscience Q3 net sales up 33% to $34M, net income $4.6M, raises FY sales growth outlook to 25-30%
--------------------------------------------------------------------------------

- Net sales $34.0M (+33% YoY); Tru Niagen sales $26.0M (+44% YoY).
- Net income $4.6M ($0.06 EPS) vs $1.9M ($0.02 EPS) prior year; adjusted EBITDA $6.4M (+120%).
- Gross margin 64.5% (+100 bps); sales & marketing expense as % of sales improved 170 bps to 25.8%.
- New FY 2025 outlook: net sales growth 25-30% (from 22-27%); reaffirms momentum in Tru Niagen and Niagen ingredients.
- Operational: launched AboutNAD platform, won NAD+ advertising challenge, expanded clinic network to 1,000+ sites.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1386570/000138657025000021/0001386570-25-000021-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1386570/000138657025000021/cdxc-20251104.htm
  HTML page:      https://secwatch.observer/filing/0001386570-25-000021

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer